19:40 , Dec 20, 2016 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer; colorectal cancer; melanoma Patient sample and mouse studies suggest CSN5 inhibitors, alone or in combination with CTLA4 inhibitors, could help treat breast cancer, colorectal cancer and melanoma. In breast cancer patients, levels...
14:19 , Nov 30, 2016 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Lymphoma; cancer In vitro , cell culture and mouse studies identified a tetrahydroimidazoazepinol-based CSN5 inhibitor that could help treat anaplastic large cell lymphoma (ALCL) and other cancers. Screening of a small molecule library in...
07:00 , Apr 15, 2013 |  BioCentury  |  Strategy

IP armamentarium

With the most stocked clinical pipeline among its RNAi peers, Alnylam Pharmaceuticals Inc. has made the leap from platform to products, building on an IP position that has enabled revenue-generating deals that footed the bill...
07:00 , Apr 15, 2013 |  BioCentury  |  Finance

De-risking money

De-risking money Cleave Bioscience Inc. 's investors allowed New Enterprise Associates to add $10 million last week on the same terms as a 2011 A round because the lion's share of money and de-risking is...
01:31 , Apr 10, 2013 |  BC Extra  |  Financial News

Cleave raises $10M in series A extension

Cancer company Cleave Biosciences Inc. (Burlingame, Calif.) raised $10 million in an extension of a series A round from new investor New Enterprise Associates. The extension brings the total raised by Cleave in the round...
07:00 , Mar 25, 2013 |  BioCentury  |  Emerging Company Profile

Cleave: Proteasome alternatives

Cleave Biosciences Inc. is developing small molecules against new targets that regulate protein homeostasis. The compounds could offer better bioavailability than existing proteasome inhibitors and work in a wider range of cancers, including solid tumors....
07:00 , Jun 13, 2011 |  BC Week In Review  |  Company News

Alnylam, Tekmira deal

Tekmira received rights from Alnylam to develop RNAi therapeutic targeting WEE1 tyrosine kinase (WEE1) and COP9 signalsome complex subunit 5 ( CSN5 ; COPS5 ; JAB1 ). Tekmira is conducting preclinical testing on WEE1/CSN5 product...
07:00 , Sep 15, 2008 |  BC Week In Review  |  Clinical News

Tekmira preclinical data

Tekmira said the National Cancer Institute has presented data showing CSN5 3/8siRNA delivered using its SNALP (stable nucleic acid-lipid particles) drug delivery technology significantly reduced tumor burden in a mouse model of HCC vs. SNALP-control...